February 9, 2026
Protecting the health and safety of plasma donors is essential to ensuring a reliable global supply of plasma-derived therapies. At the Plasma Protein Therapeutics Association (PPTA), donor well-being is a priority backed by data, standards, and continuous scientific evaluation.
Through decades of leadership in research and plasmavigilance, PPTA has helped demonstrate that plasma donation, when conducted under established regulatory frameworks, is consistent with positive donor health outcomes while meeting the growing needs of patients worldwide.
“Maintaining donor health requires more than compliance, it requires ongoing scientific inquiry and transparency,”
Michelle Fransen, MPH, Director, Study Management, PPTA
Science-Driven Confidence in Donor Safety
Recent PPTA-led studies evaluating U.S. source plasma donors across a range of donation frequencies found no significant differences in self-reported functional health and well-being when compared with new donors. Notably, most donors who discontinued donating cited convenience-related factors rather than health concerns, reinforcing the importance of access and donor experience alongside safety.
PPTA has also advanced donor protection through its International Quality Plasma Program (IQPP) and plasmavigilance initiatives, which continuously monitor donor adverse events and identify opportunities to further reduce risk. Large-scale analyses confirm that adverse event rates remain low at U.S. Food and Drug Administration (FDA)-permitted donation frequencies, while also informing targeted mitigation strategies for higher-risk donor populations.
A Shared Commitment
“A sustainable plasma system depends on trust — trust from donors, patients, and policymakers alike,”
James Knowles, Vice President, Global Regulatory Policy & Scientific Affairs, PPTA
As global demand for plasma-derived therapies continues to grow, PPTA remains committed to ensuring that donor health and safety evolve alongside scientific knowledge. Through collaboration, rigorous novel research, and proactive standards, PPTA is helping safeguard donors today while supporting patients who rely on plasma-derived therapies every day.